TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14586387
Drug: Carbon monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon monoxide (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Study: 10740559
Drug: Lidocaine 30
Normalized name: lidocaine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 30 mg pretreatment
Study: 31806099
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 3 months
Study: 31806099
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/d for 3 months (after initial no treatment)
Study: 26581199
Drug: recMAGE-A3 combined
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recMAGE-A3 combined with AS15 immunostimulant administered intramuscularly (group A, n=13)
Study: 26581199
Drug: recMAGE-A3 combined
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recMAGE-A3 combined with AS15 immunostimulant administered intradermally/subcutaneously (group B, n=12)
Study: 24814583
Drug: Perioperative selective
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative selective decontamination of the digestive tract (SDD) with colistin, tobramycin, and amphotericin B in addition to standard antibiotic prophylaxis
Study: 8826973
Drug: 2-h insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-h insulin levels in individuals who developed NIDDM
Study: 8047423
Drug: 2% nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nitroglycerin ointment
Study: 3105368
Drug: Bland ointment
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bland ointment
Study: 20151940
Drug: Zinc and
Normalized name: Zinc and/or zinc compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc and vitamin A supplementation (10 mg elemental zinc per day and one-half of a 25,000 IU vitamin A tablet every other day)
Study: 12648639
Drug: Group 2c
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2c (in-the-bag IOL implantation without opening the posterior capsule)
Study: 7871449
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin
Study: 1493986
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin
Study: 2811556
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of intravenous dexamethasone before the procedure
Study: 1108720
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of terbutaline
Study: 1108720
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of metaproterenol
Study: 31712211
Drug: CVC lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CVC lock solution with taurolidine‐citrate‐heparin
Study: 29720244
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (placebo)
Study: 30778572
Drug: L-OTM (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-OTM (equivalent to L-ITM)
Study: 24517059
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Jinhua Qinggan Granule (5 g JHG + 5 g placebo each time, 3 times daily for 5 days)
Study: 24517059
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (10 g placebo each time, 3 times daily for 5 days)
Study: 21499183
Drug: Real-time continuous
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time continuous glucose monitor with intravenous insulin infusion and rescue glucose (tight glycemic control arm)
Study: 19228385
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment every four months for 12 months
Study: 19228385
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment every four months for 12 months
Study: 19228385
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment at baseline
Study: 9267682
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg under fasting conditions
Study: 3299441
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of caffeine and mental arithmetic
Study: 3299441
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of caffeine alone
Study: 28561421
Drug: Etofenamate patch
Normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofenamate patch
Study: 25724656
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (2 μg/kg, n=10)
Study: 14594787
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg elemental calcium daily for 12 months)
Study: 1395211
Drug: Enalapril (ACE-I)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (ACE-I) added to conventional therapy including digitalis, diuretics, or vasodilators
Study: 6347233
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg orally daily for 2 weeks
Study: 26900078
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg aripiprazole
Study: 24859440
Drug: Ultralow dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow dose computerized tomography (model based iterative reconstruction)
Study: 15188499
Drug: H pylori-positive
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori-positive NUD patients receiving 10-day triple eradication therapy
Study: 9491847
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy regimen
Study: 4278962
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine solution
Study: 4278962
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical lidocaine
Study: 19616778
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of oral misoprostol immediately after evacuation followed every 6 hours for 48 hours
Study: 15570414
Drug: Biochemical markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemical markers of bone turnover (serum osteocalcin, bone-specific alkaline phosphatase, deoxypyridinoline, pyridinolines, type I collagen cross-linked C-terminal telopeptide, serum intact parathyroid hormone, 1,25 dihydroxy vitamin D)
Study: 10669269
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion with bupivacaine 1 mg/ml and fentanyl 10 mg/ml (F10)
Study: 3896217
Drug: Terbutaline by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline by wet nebulisation (5 mg, four times daily)
Study: 24576866
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (Ca-fortified beverage, 1 g·L)
Study: 12821556
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 800 IU and Vitamin C 1 g before breakfast
Study: 12821556
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 800 IU and Vitamin C 1 g (timing not specified)
Study: 8929748
Drug: Metoprolol controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol controlled release tablet (100 mg)
Study: 8929748
Drug: Bisoprolol normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol normal release tablet (10 mg)
Study: 20861631
Drug: Acid etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid etching treatment (E)
Study: 20861631
Drug: No acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acid etching treatment (NE)
Study: 15896425
Drug: Whole formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole formula diet based on lyophilised foods (Treatment Group)
Study: 84532
Drug: Protected environment-prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protected environment-prophylactic antibiotic (PEPA) program
Study: 30666480
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) with Ketac Molar Easymix® (3 M ESPE)
Study: 30666480
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) with Vitro Molar® (DFL)
Study: 19827462
Drug: Delayed Feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Feeding (DF): Water immediately postexercise, CHO-PRO solution 1 hr postexercise
Study: 19827462
Drug: Control (CON):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CON): Water (12 ml/kg BM) immediately and 1 hr postexercise
Study: 9853540
Drug: Psyllium (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (1.3 g/day of soluble fiber)
Study: 9853540
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (2.6 g/day of soluble fiber)
Study: 8299777
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IV Ig)
Study: 23669452
Drug: Parent-led tactile
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-led tactile stimulation (rubbing the ipsilateral thigh distal to the site for 15 seconds before, during, and after injections)
Study: 23537313
Drug: Weekly (W)
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly (W) schedule with gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W
Study: 23537313
Drug: 3-weekly (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-weekly (3 W) schedule with gemcitabine 1250 mg/m2 Day 1,8 + paclitaxel 175 mg/m2 Day 1 q3W
Study: 23537313
Drug: Weekly (W)
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly (W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Study: 23537313
Drug: 3-weekly (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-weekly (3 W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Study: 11692899
Drug: Prednisolone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.75 mg/kg for six months)
Study: 14635083
Drug: Dolasetron 100
Normalized name: dolasetron 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 100 mg
Study: 9398956
Drug: Dolasetron 200
Normalized name: dolasetron 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 200 mg
Study: 3296260
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with irradiation
Study: 24710760
Drug: Colesevelam 3.75
Normalized name: colesevelam 3.75 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.75 g/day
Study: 17500381
Drug: Etanercept therapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept therapy
Study: 10856099
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific dosage and duration not mentioned)
Study: 31816352
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid)
Study: 31816352
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs) with water-insoluble radiolabel (technetium-99 m-labeled ion exchange resin)
Study: 31816352
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) without water ingestion
Study: 31816352
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) with water ingestion
Study: 24425854
Drug: Daily irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily irrigation with sterile saline solution during silicone hydrogel contact lens continuous wear.
Study: 23218158
Drug: Adjunctive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive oral ziprasidone
Study: 8387071
Drug: Placebo (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (9 mg/kg dextrose)
Study: 30002707
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (OI) 1200 mg/day
Study: 18949179
Drug: captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 50 mg/kg/day (in rats)
Study: 11154142
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol (2 mg daily) for 8 weeks
Study: 9329065
Drug: 2 capsules
Normalized name: Xymogen Berberine With Insea2 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules
Study: 18822172
Drug: Trial chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial chemotherapy and FLC removal haemodialysis
Study: 18822172
Drug: Trial chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial chemotherapy and standard high flux haemodialysis
Study: 25903742
Drug: Nefopam (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (160 mg in 200 ml at a rate of 4 ml/h)
Study: 21357827
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (telmisartan and ramipril)
Study: 21357827
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blocker (telmisartan)
Study: 21205715
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone
Study: 9509952
Drug: Body temperature
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body temperature (BT), erythrocyte sedimentation rate (ESR), and serum leukocyte concentration (L)
Study: 7995154
Drug: Interferon alfa-n3
Normalized name: Interferon alfa-n3
DrugBank: Interferon alfa-n3 (DB00018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-n3 (500,000 IU, 0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Study: 7995154
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Study: 26165918
Drug: Tdap-IPV (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap-IPV (low-dose diphtheria, tetanus, acellular pertussis and inactivated polio vaccine)
Study: 26165918
Drug: Tdap +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap + OPV (low-dose diphtheria, tetanus, acellular pertussis vaccine with oral polio vaccine)
Study: 26165918
Drug: Low-dose diphtheria
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diphtheria vaccines
Study: 21709065
Drug: Ticagrelor with
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor with low-dose maintenance aspirin
Study: 21709065
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with low-dose maintenance aspirin
Study: 18413218
Drug: Diabetic subjects
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic subjects in the DCCT intensive treatment group (n=479)
Study: 17243593
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (AP)
Study: 19058889
Drug: G-Bond (GB)
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond (GB)
Study: 29205080
Drug: Normofractionated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normofractionated therapy
Study: 29205080
Drug: Hypofractionated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated therapy
Study: 15576836
Drug: 2.8 g
Normalized name: glycerin 2.8 GM per 2.7 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 g of phosphatidylinositol (PI) with food
Study: 15576836
Drug: 2.8 g
Normalized name: glycerin 2.8 GM per 2.7 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 g and 5.6 g of phosphatidylinositol (PI)
Study: 9538962
Drug: Intermittent very‐low‐calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent very‐low‐calorie diet (VLCD) for 5 consecutive days during week 2, followed by intermittent VLCD therapy for 1 day/week for 15 weeks (1‐day) or for 5 consecutive days every 5 weeks (5‐day)
Study: 9538962
Drug: Intermittent VLCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent VLCD therapy for 5 consecutive days every 5 weeks (5‐day)
Study: 9538962
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral therapy (SBT) group with a 1,500‐1,800 kcal/day diet throughout
Study: 20569068
Drug: Higher-dose BoNTA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose BoNTA (200-240 U)
Study: 20569068
Drug: Lower-dose BoNTA
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose BoNTA (120-150 U)
Study: 20569068
Drug: BoNTA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNTA (both doses)
Study: 15992393
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (10,000 lux, 1 h daily)
Study: 9030391
Drug: 3TC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3TC and zidovudine combination
Study: 10195531
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg intrathecal morphine
Study: 1800872
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg intrathecal morphine
Study: 1800872
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg intrathecal morphine (control)
Study: 30859976
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) arm
Study: 30859976
Drug: PGx-guided care
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGx-guided care arm (incongruent to congruent medication change)
Study: 7848120
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of subcutaneous sumatriptan
Study: 11875637
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g branch chain amino acids
Study: 11875637
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g branch chain amino acids
Study: 11875637
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g branch chain amino acids
Study: 10793931
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell pertussis vaccine
Study: 8330470
Drug: Torsemide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide (10 mg orally and intravenously)
Study: 24769306
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg daily for 8 weeks
Study: 15306578
Drug: OAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC treatment (omeprazole, amoxicillin, and clarithromycin)
Study: 2883683
Drug: Zotepine low
Normalized name: zotepine
DrugBank: Zotepine (DB09225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine low dosage (168 mg +/- 15 mg/die)
Study: 31046033
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of standardized Withania somnifera extract (WSE)
Study: 27789517
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents
Study: 25353657
Drug: .12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: .12% chlorhexidine spray
Study: 9745813
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic therapy
Study: 9333146
Drug: Cidofovir (0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cidofovir (0.3% or 1%) gel applied once daily for 5 days
Study: 9333146
Drug: Cidofovir (0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cidofovir (0.3% or 1%) gel
Study: 12235450
Drug: Mefloquine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (250 mg weekly)
Study: 8469191
Drug: Doxycycline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (50 mg daily) and chloroquine (300 mg weekly)
Study: 28166296
Drug: FDC Soli
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC Soli 6 mg + TOCAS
Study: 28166296
Drug: FDC Soli
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC Soli 9 mg + TOCAS
Study: 18274887
Drug: Long-term GBE
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term GBE (300 mg/daily) combined with sex therapy
Study: 18274887
Drug: Sex therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex therapy alone
Study: 16627376
Drug: Acarbose, 100
Normalized name: Acarbose, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose, 100 mg three times a day